GlobeNewswire: Elite Pharmaceuticals, Inc. Contains the last 10 of 212 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T13:05:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/11/1751053/0/en/Elite-Pharmaceuticals-Enters-into-Strategic-Marketing-Alliance-with-Lannett-For-Generic-Adderall.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall® 2019-03-11T10:45:00Z<![CDATA[NORTHVALE, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today that it has entered into a license, supply, and distribution agreement (“Agreement”) with Lannett Company, Inc. (“Lannett”). Lannett will be the exclusive U.S. distributor for two generic products that Elite and SunGen Pharma (Princeton, NJ) co-developed and co-own.]]>https://www.globenewswire.com/news-release/2019/02/11/1720447/0/en/Elite-Pharmaceuticals-Inc-Reports-Financial-Results-for-the-Third-Quarter-of-Fiscal-Year-2019-Ended-December-31-2018-and-Provides-Conference-Call-Information.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2019 Ended December 31, 2018 and Provides Conference Call Information2019-02-11T22:34:41Z<![CDATA[Conference Call Scheduled for Tuesday, February 12th at 11:30 AM EST]]>https://www.globenewswire.com/news-release/2019/02/07/1711972/0/en/Elite-Pharmaceuticals-Inc-to-Host-Conference-Call-to-Provide-Corporate-Update-and-Discuss-Third-Quarter-2019-Financial-Results-on-February-12-2019.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2019 Financial Results on February 12, 20192019-02-07T11:00:00Z<![CDATA[Financials for Third Quarter Fiscal Year 2019 Ended December 31, 2018 will be released February 11, 2019 Financials for Third Quarter Fiscal Year 2019 Ended December 31, 2018 will be released February 11, 2019]]>https://www.globenewswire.com/news-release/2019/01/03/1680050/0/en/Elite-Pharmaceuticals-and-SunGen-Pharma-File-ANDA-for-an-Antibiotic.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic2019-01-03T12:30:00Z<![CDATA[NORTHVALE, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of an antibiotic product. This is the third ANDA that Elite co-developed and filed with SunGen Pharma, LLC (“SunGen”). According to QVIA (formerly QuintilesIMS Health) data the branded product for this antibiotic and its equivalents had total annual U.S. sales of approximately $94 million for the twelve months ending September 30, 2018.]]>https://www.globenewswire.com/news-release/2018/12/10/1664279/0/en/Elite-Pharmaceuticals-and-SunGen-Pharma-Receive-FDA-Approval-for-Generic-Adderall.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall®2018-12-10T12:30:00Z<![CDATA[NORTHVALE, N.J., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for a generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg tablets. The product is a central nervous system stimulant and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. According to QVIA (formerly QuintilesIMS Health) data the branded product and its equivalents had total U.S. sales of $365 million for the twelve months ending September 30, 2018.]]>https://www.globenewswire.com/news-release/2018/11/20/1654669/0/en/Elite-Pharmaceuticals-Receives-FDA-Approval-for-Hydrocodone-and-Acetaminophen-Combo.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals Receives FDA Approval for Hydrocodone and Acetaminophen Combo2018-11-20T16:05:49Z<![CDATA[NORTHVALE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Company’s abbreviated new drug application (ANDA) for a generic version of Norco (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Norco is a combination medication and is used to help relieve moderate to moderately severe pain. The combination products of hydrocodone and acetaminophen have total annual US sales of approximately $447 million according to IQVIA (formerly QuintilesIMS Health) data.]]>https://www.globenewswire.com/news-release/2018/11/09/1649242/0/en/Elite-Pharmaceuticals-Inc-Reports-Financial-Results-for-the-Second-Quarter-of-Fiscal-Year-2019-Ended-September-30-2018-and-Provides-Conference-Call-Information.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information2018-11-09T21:45:57Z<![CDATA[Conference Call Scheduled for Monday, November 12th at 11:30 AM EST]]>https://www.globenewswire.com/news-release/2018/11/07/1646854/0/en/Elite-Pharmaceuticals-Inc-to-Host-Conference-Call-to-Provide-Corporate-Update-and-Discuss-Second-Quarter-2019-Financial-Results-on-November-12-2018.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2019 Financial Results on November 12, 20182018-11-07T12:30:00Z<![CDATA[Financials for Second Quarter Fiscal Year 2019 Ended September 30, 2018 will be released November 9, 2018]]>https://www.globenewswire.com/news-release/2018/11/05/1644957/0/en/Elite-Pharmaceuticals-Launches-Generic-Methadone-Tablets.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals Launches Generic Methadone Tablets2018-11-05T12:30:00Z<![CDATA[NORTHVALE, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced the commercial launch of generic methadone hydrochloride 5mg and 10 mg tablets by Glenmark Pharmaceuticals, Inc., USA (“Glenmark”), Elite’s marketing alliance partner.]]>https://www.globenewswire.com/news-release/2018/10/23/1625313/0/en/Elite-Pharmaceuticals-Reports-Positive-Topline-Results-from-a-Pivotal-Bioequivalence-Study.html?f=22&fvtc=4&fvtv=7189Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study2018-10-23T11:30:00Z<![CDATA[NORTHVALE, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported positive topline results from pivotal bioequivalence studies conducted for an undisclosed immediate-release antibiotic generic product which Elite co-developed with SunGen Pharma. The topline results demonstrated that the generic product was bioequivalent to the branded product in both fasted and fed studies.]]>